Access the full text.
Sign up today, get DeepDyve free for 14 days.
Y. Shigeyama, T. Pap, Peter Kunzler, B. Simmen, R. Gay, Steffen Gay (2000)
Expression of osteoclast differentiation factor in rheumatoid arthritis.Arthritis and rheumatism, 43 11
P. Villiger, M. Lotz (1992)
Expression of prepro‐enkephalin in human articular chondrocytes is linked to cell proliferation.The EMBO Journal, 11
A. Mizuno, N. Amizuka, K. Irie, A. Murakami, N. Fujise, Takeshi Kanno, Yasushi Sato, N. Nakagawa, H. Yasuda, S. Mochizuki, T. Gomibuchi, K. Yano, N. Shima, N. Washida, E. Tsuda, T. Morinaga, K. Higashio, H. Ozawa (1998)
Severe osteoporosis in mice lacking osteoclastogenesis inhibitory factor/osteoprotegerin.Biochemical and biophysical research communications, 247 3
M. Attur, M. Dave, C. Cipolletta, Pil Kang, M. Goldring, I. Patel, S. Abramson, A. Amin (2000)
Reversal of Autocrine and Paracrine Effects of Interleukin 1 (IL-1) in Human Arthritis by Type II IL-1 Decoy ReceptorThe Journal of Biological Chemistry, 275
B. Wong, D. Besser, N. Kim, J. Arron, M. Vologodskaia, M. Vologodskaia, H. Hanafusa, Yongwon Choi, Yongwon Choi (1999)
TRANCE, a TNF family member, activates Akt/PKB through a signaling complex involving TRAF6 and c-Src.Molecular cell, 4 6
T. Burgess, Y. Qian, S. Kaufman, B. Ring, G. Van, Charles Capparelli, M. Kelley, H. Hsu, W. Boyle, C. Dunstan, Sylvia Hu, D. Lacey (1999)
The Ligand for Osteoprotegerin (OPGL) Directly Activates Mature OsteoclastsThe Journal of Cell Biology, 145
H. Mankin, H. Dorfman, L. Lippiello, A. Zarins (1971)
Biochemical and metabolic abnormalities in articular cartilage from osteo-arthritic human hips. II. Correlation of morphology with biochemical and metabolic data.The Journal of bone and joint surgery. American volume, 53 3
E. Gravallese, C. Manning, A. Tsay, Akifumi Naito, C. Pan, E. Amento, S. Goldring (2000)
Synovial tissue in rheumatoid arthritis is a source of osteoclast differentiation factor.Arthritis and rheumatism, 43 2
Evan Romas, O. Bakharevski, Daphne Hards, V. Kartsogiannis, Julian Quinn, Peter Ryan, T. Martin, M. Gillespie (2000)
Expression of osteoclast differentiation factor at sites of bone erosion in collagen-induced arthritis.Arthritis and rheumatism, 43 4
B. Wong, J. Rho, J. Arron, E. Robinson, J. Orlinick, M. Chao, S. Kalachikov, Eftihia Cayani, F. Bartlett, W. Frankel, Soo Lee, Yongwon Choi (1997)
TRANCE Is a Novel Ligand of the Tumor Necrosis Factor Receptor Family That Activates c-Jun N-terminal Kinase in T Cells*The Journal of Biological Chemistry, 272
H. Yasuda, N. Shima, N. Nakagawa, K. Yamaguchi, M. Kinosaki, S. Mochizuki, Akihiro Tomoyasu, K. Yano, M. Goto, A. Murakami, E. Tsuda, T. Morinaga, K. Higashio, N. Udagawa, N. Takahashi, T. Suda (1998)
Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL.Proceedings of the National Academy of Sciences of the United States of America, 95 7
Attur Attur, Dave Dave, Cipolletta Cipolletta, Kang Kang, Goldring Goldring, Patel Patel (2000)
Reversal of autocrine and paracrine effects of interleukin 1 (IL‐1) in human arthritis by type II IL‐1 decoy receptor: potential for pharmacological interventionJ Biol Chem, 275
P. Dieppe, J. Cushnaghan, Philip Young, John Kirwan (1993)
Prediction of the progression of joint space narrowing in osteoarthritis of the knee by bone scintigraphy.Annals of the Rheumatic Diseases, 52
C. Towle, H. Hung, L. Bonassar, B. Treadwell, D. Mangham (1997)
Detection of interleukin-1 in the cartilage of patients with osteoarthritis: a possible autocrine/paracrine role in pathogenesis.Osteoarthritis and cartilage, 5 5
Y. Kong, W. Boyle, J. Penninger (2000)
Osteoprotegerin ligand: a regulator of immune responses and bone physiology.Immunology today, 21 10
J. Mansell, A.J Bailey (1998)
Abnormal cancellous bone collagen metabolism in osteoarthritis.The Journal of clinical investigation, 101 8
M. Goldring (2000)
The role of the chondrocyte in osteoarthritis.Arthritis and rheumatism, 43 9
Y. Kong, H. Yoshida, I. Sarosi, H. Tan, E. Timms, C. Capparelli, S. Morony, A. Oliveira-dos-Santos, G. Van, A. Itié, W. Khoo, A. Wakeham, C. Dunstan, D. Lacey, T. Mak, W. Boyle, J. Penninger (1999)
OPGL is a key regulator of osteoclastogenesis, lymphocyte development and lymph-node organogenesisNature, 397
D. Lacey, E. Timms, H. Tan, M. Kelley, C. Dunstan, Tim Burgess, R. Elliott, A. Colombero, G. Elliott, S. Scully, H. Hsu, J. Sullivan, N. Hawkins, E. Davy, Charles Capparelli, A. Eli, Y. Qian, S. Kaufman, I. Sarosi, V. Shalhoub, G. Senaldi, Jane Guo, J. Delaney, W. Boyle (1998)
Osteoprotegerin Ligand Is a Cytokine that Regulates Osteoclast Differentiation and ActivationCell, 93
K. Kühn, S. Hashimoto, M. Lotz (2000)
IL-1β Protects Human Chondrocytes from CD95-Induced Apoptosis1The Journal of Immunology, 164
L. Hofbauer, A. Heufelder (2001)
The role of osteoprotegerin and receptor activator of nuclear factor kappaB ligand in the pathogenesis and treatment of rheumatoid arthritis.Arthritis and rheumatism, 44 2
E. Radin, R. Rose (1986)
Role of Subchondral Bone in the Initiation and Progression of Cartilage DamageClinical Orthopaedics and Related Research, &NA;
Dirk Anderson, E. Maraskovsky, William Billingsley, W. Dougall, Mark Tometsko, E. Roux, M. Teepe, R. Dubose, D. Cosman, L. Galibert (1997)
A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell functionNature, 390
L. Lum, B. Wong, R. Josien, J. Becherer, H. Erdjument-Bromage, J. Schlöndorff, P. Tempst, Yongwon Choi, C. Blobel (1999)
Evidence for a Role of a Tumor Necrosis Factor-α (TNF-α)-converting Enzyme-like Protease in Shedding of TRANCE, a TNF Family Member Involved in Osteoclastogenesis and Dendritic Cell Survival*The Journal of Biological Chemistry, 274
N. Bucay, I. Sarosi, C. Dunstan, S. Morony, J. Tarpley, C. Capparelli, S. Scully, H. Tan, Wei-wei Xu, D. Lacey, W. Boyle, W. Simonet (1998)
osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification.Genes & development, 12 9
E. Lubberts, L. Joosten, M. Chabaud, L. Bersselaar, B. Oppers, C. Roo, C. Richards, P. Miossec, W. Berg (2000)
IL-4 gene therapy for collagen arthritis suppresses synovial IL-17 and osteoprotegerin ligand and prevents bone erosion.The Journal of clinical investigation, 105 12
I. Petersson, T. Boegård, B. Svensson, D. Heinegård, T. Saxne (1998)
Changes in cartilage and bone metabolism identified by serum markers in early osteoarthritis of the knee joint.British journal of rheumatology, 37 1
Y. Kong, U. Feige, I. Sarosi, B. Bolon, A. Tafuri, S. Morony, C. Capparelli, Ji Li, R. Elliott, Susan McCabe, Thomas Wong, G. Campagnuolo, E. Moran, E. Bogoch, G. Van, L. Nguyen, P. Ohashi, D. Lacey, E. Fish, W. Boyle, J. Penninger (1999)
Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligandNature, 402
W. Simonet, D. Lacey, C. Dunstan, M. Kelley, Ming-Shi Chang, R. Lüthy, Hung Nguyen, S. Wooden, L. Bennett, T. Boone, G. Shimamoto, M. DeRose, R. Elliott, A. Colombero, H. Tan, Geraldine Trail, J. Sullivan, E. Davy, N. Bucay, L. Renshaw-Gegg, T. Hughes, D. Hill, W. Pattison, P. Campbell, S. Sander, G. Van, J. Tarpley, P. Derby, R. Lee, W. Boyle (1997)
Osteoprotegerin: A Novel Secreted Protein Involved in the Regulation of Bone DensityCell, 89
M. Takemura, A. Harada, M. Mizuno, K. Yano, Y. Yamada (2001)
Relationship between osteoprotegerin/osteoclastogenesis inhibitory factor concentration in synovial fluid and disease severity in individuals with osteoarthritis of the knee.Metabolism: clinical and experimental, 50 1
Objective The receptor activator of nuclear factor κB (RANK) is a member of the tumor necrosis factor receptor family. It is activated by the secreted or cell surface–bound RANK ligand (RANKL). Osteoprotegerin (OPG) is a soluble nonsignaling receptor for RANKL and interferes with RANK activation. This receptor–ligand system regulates the differentiation of osteoclasts and dendritic cells. The present study examined human articular cartilage for the expression of these molecules and the role of RANKL in the regulation of chondrocyte function. Methods Normal and osteoarthritic (OA) human articular cartilage was used for explant tissue culture or for isolation of chondrocytes and cell culture. Expression of RANK, RANKL, and OPG was analyzed by immunohistochemistry, Western blotting, or reverse transcription–polymerase chain reaction. Recombinant RANKL was added to cartilage or chondrocyte cultures, and gene expression, collagenase and nitric oxide production, and NF‐κB activation were determined. Results RANK, RANKL, and OPG messenger RNA (mRNA) were expressed in normal cartilage. By immunohistochemistry, RANK, RANKL, and OPG were detected in the superficial zone of normal cartilage. OA cartilage contained increased levels of OPG mRNA, and expression of the 3 proteins extended into the midzone of OA cartilage. OPG was detected by Western blotting, and was increased in response to interleukin‐1β stimulation. OPG, RANK, and RANKL protein were also detected in cultured chondrocytes. Addition of exogenous RANKL did not activate NF‐κB, induce expression of genes encoding proinflammatory mediators in chondrocytes, or stimulate the production of collagenase and nitric oxide. Conclusion These results demonstrate the expression of OPG, RANK, and RANKL in cartilage. However, RANKL does not activate human articular chondrocytes.
Arthritis & Rheumatism – Wiley
Published: Dec 1, 2001
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.